Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cord Blood Stem Cell Transplantation | 13 | 2023 | 362 | 2.810 |
Why?
|
| Graft vs Host Disease | 26 | 2024 | 2638 | 2.640 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 28 | 2024 | 6550 | 1.930 |
Why?
|
| Hematologic Neoplasms | 14 | 2022 | 1870 | 0.920 |
Why?
|
| Transplantation Conditioning | 20 | 2024 | 2238 | 0.910 |
Why?
|
| Fetal Blood | 5 | 2023 | 482 | 0.840 |
Why?
|
| Busulfan | 12 | 2023 | 764 | 0.820 |
Why?
|
| Cytomegalovirus Infections | 3 | 2021 | 462 | 0.820 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.790 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 51 | 0.780 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2017 | 204 | 0.760 |
Why?
|
| Cystitis | 1 | 2021 | 107 | 0.730 |
Why?
|
| Opportunistic Infections | 1 | 2021 | 223 | 0.700 |
Why?
|
| Myeloablative Agonists | 6 | 2022 | 384 | 0.670 |
Why?
|
| Killer Cells, Natural | 4 | 2021 | 904 | 0.650 |
Why?
|
| Antilymphocyte Serum | 2 | 2015 | 228 | 0.570 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 2022 | 6915 | 0.570 |
Why?
|
| Regenerative Medicine | 1 | 2016 | 49 | 0.570 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1016 | 0.540 |
Why?
|
| Viremia | 2 | 2014 | 177 | 0.480 |
Why?
|
| Bone Marrow | 3 | 2021 | 2358 | 0.480 |
Why?
|
| Encephalitis, Viral | 1 | 2014 | 30 | 0.470 |
Why?
|
| Roseolovirus Infections | 1 | 2014 | 39 | 0.470 |
Why?
|
| BK Virus | 3 | 2020 | 123 | 0.460 |
Why?
|
| Herpesvirus 6, Human | 1 | 2014 | 81 | 0.450 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 1960 | 0.440 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 1763 | 0.420 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 1146 | 0.420 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 1555 | 0.380 |
Why?
|
| Allografts | 8 | 2021 | 650 | 0.380 |
Why?
|
| Vidarabine | 9 | 2022 | 1341 | 0.370 |
Why?
|
| Stem Cell Transplantation | 4 | 2021 | 1360 | 0.360 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 831 | 0.350 |
Why?
|
| Unrelated Donors | 3 | 2021 | 304 | 0.330 |
Why?
|
| Cyclophosphamide | 7 | 2024 | 3001 | 0.320 |
Why?
|
| Transplantation, Haploidentical | 4 | 2022 | 125 | 0.320 |
Why?
|
| Adult | 30 | 2024 | 77950 | 0.310 |
Why?
|
| Polyomavirus Infections | 2 | 2020 | 139 | 0.300 |
Why?
|
| Leukemia | 1 | 2016 | 1635 | 0.300 |
Why?
|
| Tumor Virus Infections | 2 | 2020 | 224 | 0.300 |
Why?
|
| Humans | 60 | 2024 | 261506 | 0.300 |
Why?
|
| Transplantation, Homologous | 7 | 2021 | 2843 | 0.290 |
Why?
|
| Virus Activation | 2 | 2018 | 228 | 0.270 |
Why?
|
| Aged | 29 | 2024 | 70117 | 0.270 |
Why?
|
| Melphalan | 5 | 2020 | 834 | 0.270 |
Why?
|
| Middle Aged | 32 | 2023 | 86204 | 0.270 |
Why?
|
| Benzoates | 2 | 2024 | 136 | 0.260 |
Why?
|
| Young Adult | 15 | 2021 | 21445 | 0.260 |
Why?
|
| Adolescent | 17 | 2024 | 31252 | 0.250 |
Why?
|
| Hydrazines | 2 | 2024 | 208 | 0.250 |
Why?
|
| Myeloproliferative Disorders | 2 | 2021 | 767 | 0.240 |
Why?
|
| Cytomegalovirus | 2 | 2018 | 482 | 0.230 |
Why?
|
| Recurrence | 8 | 2024 | 4758 | 0.230 |
Why?
|
| Medical Marijuana | 1 | 2023 | 20 | 0.220 |
Why?
|
| Cannabidiol | 1 | 2023 | 42 | 0.220 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2024 | 122 | 0.220 |
Why?
|
| Hallucinogens | 1 | 2023 | 48 | 0.210 |
Why?
|
| Cannabis | 1 | 2023 | 65 | 0.210 |
Why?
|
| Neutrophils | 2 | 2017 | 835 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2024 | 246 | 0.200 |
Why?
|
| Coronavirus OC43, Human | 1 | 2021 | 14 | 0.200 |
Why?
|
| Convalescence | 1 | 2021 | 25 | 0.200 |
Why?
|
| Common Cold | 1 | 2021 | 46 | 0.200 |
Why?
|
| Bone Marrow Transplantation | 2 | 2024 | 1581 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1664 | 0.190 |
Why?
|
| Male | 27 | 2023 | 123000 | 0.190 |
Why?
|
| Female | 27 | 2023 | 141928 | 0.170 |
Why?
|
| Prospective Studies | 7 | 2024 | 12873 | 0.170 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2020 | 406 | 0.170 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2018 | 22 | 0.170 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 222 | 0.170 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2018 | 46 | 0.170 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 568 | 0.160 |
Why?
|
| Neoplasms | 3 | 2022 | 15193 | 0.160 |
Why?
|
| Blast Crisis | 1 | 2021 | 557 | 0.160 |
Why?
|
| Pyrazoles | 2 | 2024 | 1471 | 0.150 |
Why?
|
| Pentostatin | 1 | 2017 | 119 | 0.150 |
Why?
|
| Bortezomib | 1 | 2019 | 543 | 0.150 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2016 | 22 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 2016 | 78 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 2796 | 0.140 |
Why?
|
| Lymphoma, Follicular | 1 | 2021 | 587 | 0.140 |
Why?
|
| Receptors, KIR | 1 | 2016 | 62 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 10035 | 0.140 |
Why?
|
| Disease-Free Survival | 8 | 2021 | 10001 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2021 | 527 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 846 | 0.130 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 475 | 0.130 |
Why?
|
| Histocompatibility | 1 | 2015 | 168 | 0.130 |
Why?
|
| Fucose | 1 | 2015 | 50 | 0.130 |
Why?
|
| Prognosis | 7 | 2022 | 21713 | 0.130 |
Why?
|
| Adenine Nucleotides | 1 | 2016 | 351 | 0.130 |
Why?
|
| Survival Rate | 8 | 2021 | 12221 | 0.130 |
Why?
|
| Transgenes | 1 | 2016 | 557 | 0.120 |
Why?
|
| Stem Cell Niche | 1 | 2015 | 94 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2019 | 769 | 0.120 |
Why?
|
| Incidence | 4 | 2024 | 5673 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1320 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 755 | 0.120 |
Why?
|
| Child | 7 | 2023 | 29154 | 0.120 |
Why?
|
| Arabinonucleosides | 1 | 2016 | 437 | 0.120 |
Why?
|
| Rituximab | 1 | 2019 | 1528 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2016 | 478 | 0.120 |
Why?
|
| Graft Survival | 1 | 2017 | 1062 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2016 | 546 | 0.110 |
Why?
|
| Retrospective Studies | 11 | 2024 | 37905 | 0.110 |
Why?
|
| Mortality | 1 | 2015 | 343 | 0.110 |
Why?
|
| Biopsy | 1 | 2020 | 3443 | 0.110 |
Why?
|
| Treatment Outcome | 8 | 2021 | 32848 | 0.110 |
Why?
|
| Time Factors | 3 | 2021 | 12926 | 0.100 |
Why?
|
| Tacrolimus | 2 | 2023 | 335 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2016 | 1694 | 0.100 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 3869 | 0.100 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 1688 | 0.100 |
Why?
|
| Acute Disease | 3 | 2022 | 2422 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2015 | 398 | 0.100 |
Why?
|
| Remission Induction | 3 | 2022 | 3569 | 0.100 |
Why?
|
| Lymphoma | 1 | 2019 | 1467 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2015 | 731 | 0.090 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 2864 | 0.090 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.090 |
Why?
|
| Survival Analysis | 5 | 2021 | 9180 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2017 | 2054 | 0.090 |
Why?
|
| Alleles | 1 | 2015 | 2437 | 0.080 |
Why?
|
| Cell Movement | 1 | 2016 | 2466 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2016 | 1616 | 0.080 |
Why?
|
| Risk Factors | 4 | 2024 | 17523 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 1242 | 0.080 |
Why?
|
| Antigens, CD19 | 2 | 2022 | 577 | 0.080 |
Why?
|
| Genotype | 1 | 2016 | 4109 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 2979 | 0.080 |
Why?
|
| Steroids | 2 | 2020 | 356 | 0.080 |
Why?
|
| Cytokines | 1 | 2016 | 2809 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 1429 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 15862 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 4988 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2017 | 16273 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 5112 | 0.070 |
Why?
|
| Whole-Body Irradiation | 2 | 2017 | 307 | 0.070 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 1656 | 0.070 |
Why?
|
| Age Factors | 3 | 2020 | 5377 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 4654 | 0.060 |
Why?
|
| Comorbidity | 2 | 2023 | 2352 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 3719 | 0.060 |
Why?
|
| Infant | 3 | 2015 | 13310 | 0.060 |
Why?
|
| Retreatment | 2 | 2015 | 452 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 14889 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 13658 | 0.060 |
Why?
|
| Alkylating Agents | 1 | 2024 | 78 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2022 | 1294 | 0.060 |
Why?
|
| Autografts | 1 | 2023 | 165 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 148 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 589 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2021 | 155 | 0.050 |
Why?
|
| Chimerism | 1 | 2021 | 63 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 10331 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 29 | 0.050 |
Why?
|
| Siblings | 1 | 2022 | 285 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 266 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2021 | 172 | 0.050 |
Why?
|
| Methotrexate | 1 | 2023 | 999 | 0.050 |
Why?
|
| Analgesics | 1 | 2023 | 390 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 4938 | 0.040 |
Why?
|
| Podophyllotoxin | 1 | 2019 | 63 | 0.040 |
Why?
|
| Carmustine | 1 | 2019 | 214 | 0.040 |
Why?
|
| JC Virus | 1 | 2018 | 43 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 60 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2018 | 191 | 0.040 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2018 | 33 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 810 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 324 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 553 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 1493 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 1914 | 0.040 |
Why?
|
| Viral Load | 1 | 2018 | 493 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 2315 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 1439 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2020 | 6869 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 166 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 8865 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 74 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2018 | 829 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1085 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 76 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 103 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 124 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 156 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 1382 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 698 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2015 | 447 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2015 | 471 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2014 | 441 | 0.030 |
Why?
|
| Cytarabine | 1 | 2019 | 1973 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 574 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2014 | 694 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2014 | 574 | 0.030 |
Why?
|
| Animals | 1 | 2016 | 59536 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 6100 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1033 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1972 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 4892 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6207 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 2292 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3251 | 0.020 |
Why?
|
| Pneumonia | 1 | 2014 | 751 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 4298 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5047 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 2403 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 4113 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 9244 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7702 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 5178 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 29902 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 11965 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 14289 | 0.010 |
Why?
|